The abstract is read at the publisher; the summary is JClub's.
Response-adapted mosunetuzumab followed by polatuzumab vedotin and obinutuzumab achieved 86% complete response in 42 untreated follicular and marginal zone lymphoma patients.
- Why it matters: Standard chemoimmunotherapy remains the default for untreated indolent B-cell non-Hodgkin lymphoma, but an optimized chemotherapy-free regimen is needed to balance efficacy and safety.
- What they did: Patients received eight cycles of mosunetuzumab, then non-CR patients by PET-CT received six cycles of polatuzumab vedotin plus obinutuzumab; best ORR/CR by fluorodeoxyglucose-PET-CT was assessed.
- The result: End-of-treatment ORR was 100% with 86% CR, and with 34 months median follow-up, 2-year PFS was 89% and 2-year overall survival was 100%, with grade 1 cytokine release syndrome in 64% and no tocilizumab use.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.